Adaptive Biotechnologies (ADPT) Accumulated Expenses (2018 - 2026)

Adaptive Biotechnologies has disclosed Accumulated Expenses across 9 years of filings, most recently posting $10.7 million for Q2 2026.

• In Q2 2026, Accumulated Expenses rose 9.8% year-over-year to $10.7 million; the TTM figure through Jun 2026 stood at $10.7 million (up 9.8% YoY), while the FY2025 annual figure was $17.0 million, up 7.29% from the prior year.
• Accumulated Expenses came in at $10.7 million for Q2 2026 at Adaptive Biotechnologies, up from $7.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $17.0 million in Q4 2025 to a low of $7.5 million in Q1 2026.
• Average Accumulated Expenses over 5 years is $11.3 million, with a median of $10.6 million recorded in 2023.
• Year-over-year, Accumulated Expenses dropped 27.82% in 2022 and rose 15.86% in 2024.
• Over 5 years, Accumulated Expenses stood at $15.9 million in 2022, then retreated by 14.12% to $13.7 million in 2023, then climbed by 15.73% to $15.8 million in 2024, then increased by 7.29% to $17.0 million in 2025, then plunged by 37.32% to $10.7 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $10.7 million in Q2 2026, $7.5 million in Q1 2026, and $17.0 million in Q4 2025.